上海颀航医药科技发展

Shanghai Qihang Pharmaceutical Technology Development is a Chinese biopharmaceutical company established in 2022 and based in Shanghai. The company focuses on the research and development of small molecule therapeutics for metabolic and endocrine disorders, particularly targeting gout and hyperuricemia. Its lead program, BCM896 (Topiroxostat sustained-release tablets), is a selective xanthine dehydrogenase inhibitor designed to reduce uric acid production. BCM896 has advanced into Phase 1 clinical development in China, with completed pharmacokinetic studies comparing sustained-release formulations to standard tablets in healthy participants.